How should chorea be treated, including first‑line and alternative pharmacologic options and management of underlying causes?

Treatment of Chorea

For symptomatic treatment of chorea, VMAT2 inhibitors (tetrabenazine, deutetrabenazine, or valbenazine) are the first-line pharmacologic agents, with dopamine receptor blockers (haloperidol, sulpiride, quetiapine) reserved as second-line alternatives when VMAT2 inhibitors are contraindicated, poorly tolerated, or insufficiently effective. 1, 2

Initial Diagnostic Evaluation

Before initiating symptomatic treatment, identify and address reversible or treatable underlying causes:

• Brain MRI without contrast is the optimal imaging modality to identify structural lesions, vascular abnormalities, basal ganglia changes, and neurodegenerative patterns 3, 4
• Essential laboratory testing includes serum ceruloplasmin (to exclude Wilson disease), thyroid function, calcium, phosphorus, parathyroid hormone, glucose, and alpha-fetoprotein if ataxia-telangiectasia is suspected 4
• Genetic testing for Huntington's disease (CAG repeat expansion in huntingtin gene) should be performed when clinically suspected 3, 4
• Streptococcal serology (antistreptolysin O, anti-deoxyribonuclease B, or streptozyme) in children with acute-onset chorea to diagnose Sydenham's chorea 4

Etiology-Specific Treatment (Priority Over Symptomatic Therapy)

Autoimmune/Inflammatory Chorea

• For systemic lupus erythematosus-related chorea: Glucocorticoids alone or combined with immunosuppressive agents (azathioprine or cyclophosphamide) 5, 3
• For refractory cases with generalized lupus activity: Pulse intravenous methylprednisolone combined with intravenous cyclophosphamide 5, 3
• For antiphospholipid antibody-associated chorea: Antiplatelet and/or anticoagulation therapy, especially when other antiphospholipid syndrome manifestations are present 5, 4

Sydenham's Chorea

• For severe, drug-resistant, or disabling cases: IV methylprednisolone followed by oral deflazacort, or oral deflazacort alone for mild-to-moderate cases 6
• This approach is effective across different clinical presentations (chorea paralytica, hemichorea, classic chorea) with minimal side effects 6

Drug-Induced Chorea

• Discontinue the offending agent (particularly neuroleptics causing tardive dyskinesia) and monitor patients on long-term neuroleptics periodically 4

Metabolic Causes

• Correct underlying metabolic disturbances: thyroid dysfunction, calcium-phosphate abnormalities, glucose disturbances, or aluminum toxicity in hemodialysis patients 4

First-Line Symptomatic Pharmacologic Treatment

Initiate symptomatic treatment only when chorea interferes with daily functioning, causes social isolation, gait instability, falls, or physical injury. 7

VMAT2 Inhibitors (Preferred First-Line)

• Tetrabenazine: Start low dose and titrate gradually with close monitoring for adverse effects 7, 2
• Deutetrabenazine: Similar efficacy to tetrabenazine with suggested fewer peak-dose side effects 1, 7
• Valbenazine: FDA-approved alternative for reducing chorea severity in Huntington's disease 4
• Mechanism: These agents cause striatal dopamine depletion through presynaptic VMAT2 inhibition 2
• Common pitfall: Rapid dose escalation can precipitate depression, parkinsonism, or akathisia; always start low and titrate slowly 7

Second-Line Symptomatic Pharmacologic Treatment

Dopamine Receptor Blockers (Antipsychotics)

Use when VMAT2 inhibitors are contraindicated, poorly tolerated, or insufficiently effective:

• Haloperidol: Typical antipsychotic that antagonizes dopamine receptors; effective but carries higher risk of extrapyramidal symptoms 1, 4
• Sulpiride: Selective D₂/D₃ receptor antagonist (available in European countries); improves choreic movements 1, 7
• Quetiapine: Atypical antipsychotic with lower risk of extrapyramidal symptoms; preferred when tolerability is a concern 1
• Tiapride: Preferred first-choice option among HD experts in European countries 7
• Olanzapine and risperidone: Also show beneficial effects on motor symptom severity and psychiatric symptoms 7

Critical caveat: All antipsychotics carry risks of extrapyramidal symptoms, tardive dyskinesia, and metabolic adverse effects; weigh benefits against potential harms 1

Alternative Symptomatic Agents

• Anti-epileptics (carbamazepine, valproate): Used in Sydenham's chorea and other childhood chorea cases 8, 6
• Anti-glutamatergics: Occasionally employed but limited evidence 2
• Pridopidine ("dopamine stabilizer"): Currently under investigation in clinical trials 7, 2

Non-Pharmacologic Management

• Physical therapy: Addresses motor dysfunction and gait instability 1
• Occupational therapy: Assists with activities of daily living impacted by choreiform movements 1, 3
• Speech therapy: Beneficial for orofacial chorea affecting speech and swallowing 3
• Deep brain stimulation: Reserved for patients with disabling chorea despite optimal medical therapy 2

Emerging Disease-Modifying Therapies (Huntington's Disease)

• Tominersen (antisense oligonucleotide): Phase III GENERATION HD1 trial was halted in 2021 due to faster neurologic decline in high-dose groups; phase II GENERATION HD2 trial evaluating lower doses (60 mg and 100 mg every 16 weeks) with completion anticipated in 2027 1
• CRISPR-based gene editing: Remains in preclinical development with challenges including off-target effects, blood-brain barrier delivery, and limited benefit in late-stage disease 1

Pediatric-Specific Considerations

• Sydenham's chorea accounts for 96% of acute-onset chorea in children in endemic regions; approximately 30% present with unilateral (hemichorea) movements 4
• Associated features: Behavioral changes (46%), dysarthria (67%), gait disturbance (51%), deteriorating handwriting (29%), and concurrent carditis (44%) 4
• Treatment decision: Base symptomatic treatment on functional impact; no randomized controlled trials exist for childhood chorea, so recommendations rely on clinical experience and case reports 8